These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24111907)

  • 1. An update on the chemistry and medicinal chemistry of novel antimycobacterial compounds.
    Branco FS; Pinto AC; Boechat N
    Curr Top Med Chem; 2013; 13(22):2808-49. PubMed ID: 24111907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
    Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J
    Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid: first global approval.
    Ryan NJ; Lo JH
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC; Martin A
    Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.
    Patel RV; Riyaz SD; Park SW
    Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filling the pipeline - new drugs for an old disease.
    Stehr M; Elamin AA; Singh M
    Curr Top Med Chem; 2014; 14(1):110-29. PubMed ID: 24236723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial watch: Novel antimicrobial fights TB resistance.
    Crunkhorn S
    Nat Rev Drug Discov; 2012 Aug; 11(8):590. PubMed ID: 22814418
    [No Abstract]   [Full Text] [Related]  

  • 15. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anti-tuberculosis drugs with novel mechanisms of action.
    Rivers EC; Mancera RL
    Curr Med Chem; 2008; 15(19):1956-67. PubMed ID: 18691051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
    Tandon R; Nath M
    Mini Rev Med Chem; 2017; 17(6):549-570. PubMed ID: 27280980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.